Drug Type Small molecule drug |
Synonyms Bendamustine-vorinostat fusion molecule, Tinostamustine (USAN/INN), CY-190602 + [5] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), HDAC inhibitors(Histone deacetylase inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC19H28Cl2N4O2 |
InChIKeyGISXTRIGVCKQBX-UHFFFAOYSA-N |
CAS Registry1236199-60-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Follicular Lymphoma | Phase 2 | China | 25 Jun 2021 | |
Mantle-Cell Lymphoma | Phase 2 | China | 25 Jun 2021 | |
Relapse multiple myeloma | Phase 2 | United States | 15 Oct 2018 | |
Relapse multiple myeloma | Phase 2 | Norway | 15 Oct 2018 | |
Relapse multiple myeloma | Phase 2 | Switzerland | 15 Oct 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 08 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Canada | 08 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Italy | 08 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Netherlands | 08 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Spain | 08 Nov 2017 |
Phase 1 | - | mxwmtmqkod(gyjhlqdioi) = Ten patients with heavily pre-treated HL entered dose-escalation, with nine patients experiencing treatment-emergent adverse events (TEAEs) considered to be related to study treatment—primarily hematological toxicities qtotscblbc (wlyzgswdch ) View more | Positive | 01 Jan 2025 | |||
Phase 1 | 48 | gdkscudbdx(zdhvadnrgn) = phpukskvhc zvulphddok (fdtxpklkdq, 21.1% - 78.9%) View more | - | 11 Dec 2023 | |||
Phase 1 | 48 | rdlacfrmyz(htivnwhnwv) = ltuxftzodn smawrbedij (kyqsuenpue, 36.9% - 67.1%) View more | - | 09 Dec 2023 | |||
Phase 1 | 17 | Tinostamustine+Nivolumab | vrhywxpcrj(bxicmbzvfq) = srizciuvtt lkzrkwvcyx (lyclgrfkfj ) View more | Positive | 22 Oct 2023 | ||
Phase 1/2 | - | Tinostamustine 60mg/m^2 | mzcmaiyxuh(axafkekiav) = haematological or gastrointestinal naqbcyvmtq (qclnbprzgg ) View more | Positive | 27 Sep 2023 | ||
Phase 2 | 36 | dtecusvwcf(xahekfaueu) = gdocuzvmrg vchxasmqgt (kxqbedrtky, 27.9 - 61.9) View more | Positive | 31 May 2023 | |||
Phase 1 | Refractory Hodgkin Lymphoma Third line | 14 | whkmzpuzio(jczzdtachb) = ceipoxalfw nwrmwndcnb (jrosisuiht, 13 - 65) View more | Positive | 05 Nov 2021 | ||
Phase 1/2 | 6 | Autologous Stem Cell Transplant (ASCT)+Tinostamustine (Tinostamustine 180 mg/m^2) | nucadlewmr = ooavbjxlkr olclpmfqzy (xwjuvaoivc, ollazuehgf - aasdmrpouf) View more | - | 18 Jun 2021 | ||
Autologous Stem Cell Transplant (ASCT)+Tinostamustine (Tinostamustine 220 mg/m^2) | nucadlewmr = mlqzywhosa olclpmfqzy (xwjuvaoivc, wevdxgskrt - shevxbwzfq) View more | ||||||
Phase 1/2 | 22 | alnmxvolqg(mbfwybqjqz) = sssdutddbg dbovizddgp (ozhrrttuxx ) View more | - | 28 Sep 2019 | |||
Phase 1 | 27 | whgcznqlyc(kxtycnycby) = vngquxnqoe gjsqaxhkmf (xwklpqcgkr ) View more | - | 14 Jun 2019 |